These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 12923636)

  • 1. Comparison of human lung cancer/SCID mouse tumor xenografts and cell culture growth with patient clinical outcomes.
    Anderson TM; Hess SD; Egilmez NK; Nwogu CE; Lenox JM; Bankert RB
    J Cancer Res Clin Oncol; 2003 Oct; 129(10):565-8. PubMed ID: 12923636
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Survival and treatment of non-small cell lung cancer stage I-II treated surgically or with stereotactic body radiotherapy: patient and tumor-specific factors affect the prognosis.
    Mokhles S; Nuyttens JJ; Maat AP; Birim Ö; Aerts JG; Bogers AJ; Takkenberg JJ
    Ann Surg Oncol; 2015 Jan; 22(1):316-23. PubMed ID: 24962941
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lymphovascular invasion in non-small-cell lung cancer: implications for staging and adjuvant therapy.
    Higgins KA; Chino JP; Ready N; D'Amico TA; Berry MF; Sporn T; Boyd J; Kelsey CR
    J Thorac Oncol; 2012 Jul; 7(7):1141-7. PubMed ID: 22617241
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Relationship between tumor size and survival among patients with resection of multiple synchronous lung cancers.
    Tanvetyanon T; Robinson L; Sommers KE; Haura E; Kim J; Altiok S; Bepler G
    J Thorac Oncol; 2010 Jul; 5(7):1018-24. PubMed ID: 20453687
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A randomized phase 2 study of paclitaxel and carboplatin with or without conatumumab for first-line treatment of advanced non-small-cell lung cancer.
    Paz-Ares L; Bálint B; de Boer RH; van Meerbeeck JP; Wierzbicki R; De Souza P; Galimi F; Haddad V; Sabin T; Hei YJ; Pan Y; Cottrell S; Hsu CP; RamLau R
    J Thorac Oncol; 2013 Mar; 8(3):329-37. PubMed ID: 23370314
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lymph node ratio may predict the benefit of postoperative radiotherapy in non-small-cell lung cancer.
    Urban D; Bar J; Solomon B; Ball D
    J Thorac Oncol; 2013 Jul; 8(7):940-6. PubMed ID: 23695418
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Elevated expression of BIRC6 protein in non-small-cell lung cancers is associated with cancer recurrence and chemoresistance.
    Dong X; Lin D; Low C; Vucic EA; English JC; Yee J; Murray N; Lam WL; Ling V; Lam S; Gout PW; Wang Y
    J Thorac Oncol; 2013 Feb; 8(2):161-70. PubMed ID: 23287853
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Overexpression of the mammalian target of rapamycin: a novel biomarker for poor survival in resected early stage non-small cell lung cancer.
    Dhillon T; Mauri FA; Bellezza G; Cagini L; Barbareschi M; North BV; Seckl MJ
    J Thorac Oncol; 2010 Mar; 5(3):314-9. PubMed ID: 20093977
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Erlotinib in advanced non-small cell lung cancer: efficacy and safety findings of the global phase IV Tarceva Lung Cancer Survival Treatment study.
    Reck M; van Zandwijk N; Gridelli C; Baliko Z; Rischin D; Allan S; Krzakowski M; Heigener D
    J Thorac Oncol; 2010 Oct; 5(10):1616-22. PubMed ID: 20736854
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic implications of neuroendocrine differentiation and hormone production in patients with Stage I nonsmall cell lung carcinoma.
    Pelosi G; Pasini F; Sonzogni A; Maffini F; Maisonneuve P; Iannucci A; Terzi A; De Manzoni G; Bresaola E; Viale G
    Cancer; 2003 May; 97(10):2487-97. PubMed ID: 12733148
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CXCR4 overexpression is associated with poor outcome in females diagnosed with stage IV non-small cell lung cancer.
    Otsuka S; Klimowicz AC; Kopciuk K; Petrillo SK; Konno M; Hao D; Muzik H; Stolte E; Boland W; Morris D; Magliocco AM; Bebb DG
    J Thorac Oncol; 2011 Jul; 6(7):1169-78. PubMed ID: 21623238
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Frequency and Prognostic Impact of Pathological Microscopic Vascular Invasion According to Tumor Size in Non-Small Cell Lung Cancer.
    Shimada Y; Saji H; Kato Y; Kudo Y; Maeda J; Yoshida K; Hagiwara M; Matsubayashi J; Kakihana M; Kajiwara N; Ohira T; Ikeda N
    Chest; 2016 Mar; 149(3):775-85. PubMed ID: 26379115
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ly6/uPAR-related protein C4.4A as a marker of solid growth pattern and poor prognosis in lung adenocarcinoma.
    Jacobsen B; Muley T; Meister M; Dienemann H; Christensen IJ; Santoni-Rugiu E; Lærum OD; Ploug M
    J Thorac Oncol; 2013 Feb; 8(2):152-60. PubMed ID: 23287851
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic factors for survival of stage I nonsmall cell lung cancer patients : a population-based analysis of 19,702 stage I patients in the California Cancer Registry from 1989 to 2003.
    Ou SH; Zell JA; Ziogas A; Anton-Culver H
    Cancer; 2007 Oct; 110(7):1532-41. PubMed ID: 17702091
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lung carcinoma with rhabdoid component. A series of seven cases associated with uncommon types of non-small cell lung carcinomas and alveolar entrapment.
    Izquierdo-Garcia FM; Moreno-Mata N; Herranz-Aladro ML; Cañizares MA; Alvarez-Fernandez E
    Histol Histopathol; 2010 Oct; 25(10):1287-95. PubMed ID: 20712013
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic impact of number of resected and involved lymph nodes at complete resection on survival in non-small cell lung cancer.
    Saji H; Tsuboi M; Yoshida K; Kato Y; Nomura M; Matsubayashi J; Nagao T; Kakihana M; Usuda J; Kajiwara N; Ohira T; Ikeda N
    J Thorac Oncol; 2011 Nov; 6(11):1865-71. PubMed ID: 21964529
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic significance of TAZ expression in resected non-small cell lung cancer.
    Xie M; Zhang L; He CS; Hou JH; Lin SX; Hu ZH; Xu F; Zhao HY
    J Thorac Oncol; 2012 May; 7(5):799-807. PubMed ID: 22481233
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Performance status and smoking status are independent favorable prognostic factors for survival in non-small cell lung cancer: a comprehensive analysis of 26,957 patients with NSCLC.
    Kawaguchi T; Takada M; Kubo A; Matsumura A; Fukai S; Tamura A; Saito R; Maruyama Y; Kawahara M; Ignatius Ou SH
    J Thorac Oncol; 2010 May; 5(5):620-30. PubMed ID: 20354456
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Survival differences by gender for resected non-small cell lung cancer: a retrospective analysis of 12,509 cases in a Japanese Lung Cancer Registry study.
    Sakurai H; Asamura H; Goya T; Eguchi K; Nakanishi Y; Sawabata N; Okumura M; Miyaoka E; Fujii Y;
    J Thorac Oncol; 2010 Oct; 5(10):1594-601. PubMed ID: 20736855
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Osteoblastic reaction in non-small cell lung carcinoma and its association to epidermal growth factor receptor tyrosine kinase inhibitors response and prolonged survival.
    Pluquet E; Cadranel J; Legendre A; Faller MB; Souquet PJ; Zalcman G; Perol M; Fraboulet G; Oliveiro G; De Fraipont F; Quoix E; Lantuejoul S; Milleron B; Moro-Sibilot D
    J Thorac Oncol; 2010 Apr; 5(4):491-6. PubMed ID: 20195171
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.